Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Cash from Investing Activities (2021 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Cash from Investing Activities for 4 consecutive years, with -$123000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Cash from Investing Activities rose 37.88% to -$123000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was -$123000.0, a 62.61% increase, with the full-year FY2024 number at -$254000.0, up 66.97% from a year prior.
  • Cash from Investing Activities was -$123000.0 for Q4 2024 at Werewolf Therapeutics, down from -$3000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$3000.0 in Q3 2024 to a low of -$2.0 million in Q3 2022.
  • A 4-year average of -$320750.0 and a median of -$145500.0 in 2023 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 1815.69% in 2022, then skyrocketed 98.64% in 2024.
  • Werewolf Therapeutics' Cash from Investing Activities stood at -$272000.0 in 2021, then plummeted by 90.44% to -$518000.0 in 2022, then soared by 61.78% to -$198000.0 in 2023, then skyrocketed by 37.88% to -$123000.0 in 2024.
  • Per Business Quant, the three most recent readings for HOWL's Cash from Investing Activities are -$123000.0 (Q4 2024), -$3000.0 (Q3 2024), and -$17000.0 (Q2 2024).